2.23
2.23 (-1.06%)
As of Sep 20, 2023
Paratek Pharmaceuticals, Inc. [PRTK]
Source:
Company Overview
We area commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government andmilitary use. Our United States, or U.S., Food and Drug Administration, or FDA, approved commercial product, NUZYRA(omadacycline) is a once-daily oral and intravenous antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia, or CABP, and acute skin and skin structure infections, or ABSSSI, caused by susceptible pathogens. SEYSARA(sarecycline) is an FDA-approved product with respect to which we have exclusively licensed in the U.S.
| Country | United States |
| Headquarters | boston, massachusetts |
| Phone Number | (617) 807-6600 |
| Industry | manufacturing |
| CEO | Evan Loh, M.D. |
| Website | www.paratekpharma.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $40 |
| Operating Profit | $-9.4 |
| Net Income | $-14.6 |
| Net Cash | $8.4 |
Profit Ratios
| Gross Margin | $35.6 |
| Operating Margin | -23.5 |
| Profit as % of Revenues | 89.1% |
| Profit as % of Assets | -9,143.3% |
| Profit as % of Stockholder Equity | 7,227.2% |
Management Effectiveness
| Return on Equity | 25.3% |
| Return on Assets | -35% |
| Turnover Ratio | 251.3% |
| EBITA |
Balance Sheet and Cash Flow Measures
| Total Assets | $145.8 |
| Total Liabilities | $347.2 |
| Operating Cash Flow | $9.3 |
| Investing Cash Flow | $-0 |
| Financing Cash Flow | $-0.8 |
